TABRIX

• 72190 - Other research and experimental development on natural sciences and engineering

TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections. TaBriX's initial focus is on the treatment of drug-resistant TB... TaBriX targets are also present in the priority list organisms of the World Health Organisation, responsible for drug-resistant infections... TaBriX focuses on the development of drugs that target novel, unexplored biological pathways to fight difficult-to-treat infections, such as tuberculosis, and tackle the global threat of drug resistance.

Also known as: TaBriX Company, TABRIX LIMITED

Registration numbers: 13228190 (CH)

Primary location: MANCHESTER ENGLAND